The Food and Drug Administration (FDA) has approved Alyftrek ™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one ...

BX-004 is under development for the treatment of cystic fibrosis, non-cystic fibrosis bronchiectasis and resistant pseudomonas aeruginosa infections. It is administered as inhalational formulation.

Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.

The US Food and Drug Administration has approved Alyftrek, a once-daily oral combination of vanzacaftor, tezacaftor, and ...

Use of antibiotics by the newborn or mother while breastfeeding, dietary changes, bacterial infections, parasite infections, and cystic fibrosis are among the major causes of diarrhea in infants. Thus ...

Mehdi obtained his MSc Degree in “Molecular Interactions and Therapeutics” from Jules Verne University of Amiens (France). In ...

ALYFTREK™ is approved for patients 6 years and older with at least one responsive mutation, including 31 additional mutations not responsive to other CFTR ...

Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple ...

Whether you are dealing with severe consequences of cystic fibrosis or want to get ahead the symptoms, these tips will help.

LOS GATOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on recent ...

Armata Pharmaceuticals (ARMP) announced “encouraging” topline results from its Phase 2 trial evaluating AP-PA02, a novel, inhaled multi-phage therapeutic for the treatment of chronic pulmonary ...